Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. develops DNA and mRNA synthesis solutions for therapeutic discovery, using automated systems and enzymatic synthesis technology that support on-site biofoundry workflows. Company news centers on the Gibson SOLA platform, BioXp systems, mRNA synthesis offerings, and customer adoption in areas such as biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.
Recurring updates also include licensing agreements, laboratory automation collaborations, private financing activity, financial results, restructuring effects, and capital-market actions such as reverse stock splits and trading-status changes. The company has described a commercial focus on Gibson SOLA and BioXp mRNA solutions while reporting product, collaboration, service, and royalty revenue categories.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.